Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Combination therapy that includes a novel antibody is superior to immunotherapy alone for advanced non-small-cell lung cancer.
Screening is recommended for current and former heavy smokers ages 50 to 80, but HIV-positive people may benefit from earlier screening.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
Emotions play a powerful role in living with cancer, a truth AJ Patel learned a decade ago when he was diagnosed with metastatic lung cancer
November is Lung Cancer Awareness Month.
Although most people screened meet the USPSTF criteria, only one in five returned for a follow-up test a year later.
The checkpoint inhibitor is now approved for people with advanced non-small-cell lung cancer regardless of PD-L1 biomarker levels.
However, lung cancer incidence among HIV-positive people has fallen over the past two decades.
Lung cancer continues to be one of the most common cancers, claiming more lives yearly than breast, colon and prostate cancers combined.
Now patients with non-small cell lung cancer have another targeted therapy option.
Regular screening can detect lung cancer early, when it’s easier to treat.
The combination of target drugs Tafinlar-Mekinist is approved for nearly any type of advanced solid tumor that has the BRAF gene mutation.
Can a person’s immune system help prevent two types of non-small-cell lung cancer? Here’s how Robert Keith, MD, hopes to find out.
A new report tracks the most prominent cancers for men and women and finds substantial racial disparities in cancer treatment.
After losing his never-smoker wife to lung cancer in 2011, the former NFL linebacker tackles stigma and raises awareness.
An Army veteran, retired firefighter and farmer, Jeff Meckstroth, 65, lives in Ohio. He has Stage IV metastatic non-small-cell lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.